Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 1179-1187

  Takane, Hiroshi ^a   Kobayashi, Daisuke ^b   Hirota, Takeshi ^b   Kigawa, Junzo ^a   Terakawa, Naoki ^a   Otsubo, Kenji ^a   Ieiri, Ichiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; LUCIFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR;

ARTICLE; ASIAN; BINDING SITE; BLOOD SAMPLING; CAUCASIAN; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; REPORTER GENE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CELLS, CULTURED; CPG ISLANDS; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, MDR; HAPLOTYPES; HUMANS; LIVER; LUCIFERASES; METHYLATION; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PLACENTA; PLASMIDS; PREGNANCY; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VARIATION (GENETICS);

EID: 10044270854     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.069724     Document Type: Article

References (38)

1. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889-1896.
2. Brandeis M, Frank D, Keshetz I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A, and Cedar H (1994) Sp1 elements protect a CpG island from de novo methylation. Nature (Lond) 371:435-438.
3. Calado RT, Falcao RP, Garcia AB, Gabellini SM, Zago MA, and Franco RF (2002) Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 87:564-568.
4. Cornwell MM and Smith DE (1993) SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268:19505-19511.
5. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, and Liggett SB (2000) Complex promoter and coding region 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acd Sci USA 97:10483-10488.
6. El-Osta A, Kanatharidis P, Zalcberg JR, and Wolffe AP (2002) Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 22:1844-1857.
7. Fromm MF (2002) The influence of MDR1 polymorphisms on p-glycoprotein expression and function in humans. Adv Drug Deliver Rev 54:1295-1320.
8. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, and Paul CL (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827-1831.
9. Fryxell KB, McGee SB, Simoneaux DK, Willman CL, and Cornwell MM (1999) Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. Leukemia 13:910-917.
10. Goldsmith ME, Madden MJ, Morrow CS, and Cowan KH (1993) A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 268:5856-5860.
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Casscorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (1999) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
12. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, and Okumura K (2002) Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res (NY) 19:1581-1584.
13. Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, et al. (2000) Catalytic activity of three variants (Ile, Leu and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 22:237-244.
14. Ishikawa T, Hirano H, Onishi Y, Sakurai A, and Tarui S (2004) Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 19:1-14.
15. Jin S and Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18:4377-4384.
16. Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584-594.
17. Jones PA and Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science (Wash DC) 293:1068-1070.
18. Judson R, Stephens JC, and Windemuth A (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics 1:15-26.
19. Kim RB and Tirona RG (2002) Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliver Rev 54:1343-1352.
20. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, and Kuwano M (1990) Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J Biol Chem 265:19690-19696.
21. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Young JD, Taylor T, et al. (2003) Sequence diversity and haplotype structure in the human ABCB1(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-484.
22. Macleod D, Ali RR, and Bird A (1998) An alternative promoter in the mouse major histocompatibility complex class II I-Aβ gene: implications for the origin of CpG islands. Mol Cell Biol 18:4433-4443.
23. Macleod D, Charlton J, Mullins J, and Bird AP (1994) Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev 8:2282-2292.
24. Madden MJ, Morrow CS, Nakagawa M, Goldsmith ME, Fairchild CR, and Cowan KH (1993) Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 268:8290-8297.
25. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, and Okumura K (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71:297-303.
26. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Oshima K, Kozuru M, Komatsu H, Ueda R, and Kuwano M (1998) Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92:4296-4307.
27. Ogura M, Takatori T, and Tsuruo T (1992) Purification and characterization of NF-R1 that regulates the expression of the human multidrug resistance (MDR1) gene. Nucleic Acids Res 20:5811-5817.
28. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, et al. (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res (NY) 18:1400-1404.
29. Singal R and Ginder GD (1999) DNA methylation. Blood 93:4059-4070.
30. Sparreboom A, Danesi R, Ando Y, Chan J, and Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 6:71-84.
31. Sundseth R, MacDonald G, Ting J, and King AC (1997) DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 51:963-971.
32. Takane H, Ieiri I, and Otsubo K (2003) Genetic polymorphisms of organic anion and cation transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Curr Pharmacogenomics 1:245-257.
33. Takeuchi T, Nakamura S, Kayasuga A, Isa S, and Sato K (2000) Multiple elements for negative regulation of the rat catalase gene expression in dedifferentiated hepatoma cells. J Biochem 128:1025-1031.
34. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137-1143.
35. Tang K, Ngoi SM, Gwee PC, Chua JMZ, Lee EJD, Chong SS, and Lee CGL (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437-450.
36. Toda Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, Nagayama J, Nakagawa M, Naito S, and Kuwano M (2000) MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6:4618-4627.
37. Ueda K, Pastan I, and Gottesman MM (1987) Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 262:17432-17436.
38. van Groenigen M, Valentijn LJ, and Baas F (1993) Identification of a functional initiator sequence in the human MDR1 promoter. Biochim Biophys Acta 1172:138-146.